Prime Editing Shows Potential for Genetic Disease Treatment Amidst In Vivo Application Challenges
Prime editing, a gene-editing technology developed in 2019, holds the potential to repair the majority of known disease-causing human mutations. Despite its promise, the technology has not yet been widely adopted for in vivo treatment of genetic diseases. The only publicly disclosed clinical application involves editing cells outside the body before reintroducing them to patients.
Prime editing technology, initially developed in 2019, offers significant potential for addressing a broad spectrum of genetic disorders. The method is capable of repairing the majority of known disease-causing human mutations.
Despite its capabilities, prime editing has not yet seen widespread use for treating genetic diseases directly within the human body, a process known as in vivo application. Current developments indicate limitations in this area.
Currently, the sole clinical application of prime editing that has been publicly announced involves an ex vivo approach. In this method, cells are edited outside the body before being transplanted back into the patient.
According to Phys.org, this approach highlights the current state of prime editing technology as it progresses towards broader clinical utility.
